Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Target Price at $3.92

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has been given a consensus rating of “Reduce” by the nine brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $4.30.

A number of brokerages recently issued reports on PLRX. Wall Street Zen upgraded Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Thursday, January 22nd.

Insider Transactions at Pliant Therapeutics

In other Pliant Therapeutics news, CEO Bernard Coulie sold 89,375 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $1.28, for a total transaction of $114,400.00. Following the completion of the transaction, the chief executive officer owned 505,601 shares in the company, valued at $647,169.28. The trade was a 15.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 8.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pliant Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PLRX. Rangeley Capital LLC grew its stake in Pliant Therapeutics by 20.4% in the 2nd quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock worth $70,000 after acquiring an additional 10,220 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Pliant Therapeutics by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 113,383 shares of the company’s stock valued at $138,000 after purchasing an additional 15,349 shares during the period. Algert Global LLC grew its stake in Pliant Therapeutics by 17.7% in the third quarter. Algert Global LLC now owns 104,382 shares of the company’s stock worth $154,000 after purchasing an additional 15,692 shares in the last quarter. Eversept Partners LP increased its holdings in Pliant Therapeutics by 2.1% during the 4th quarter. Eversept Partners LP now owns 842,023 shares of the company’s stock worth $1,027,000 after purchasing an additional 17,429 shares during the period. Finally, Engineers Gate Manager LP raised its position in Pliant Therapeutics by 139.4% during the 2nd quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock valued at $36,000 after purchasing an additional 18,300 shares in the last quarter. 97.30% of the stock is owned by institutional investors.

Pliant Therapeutics Price Performance

NASDAQ:PLRX opened at $1.27 on Tuesday. The firm has a market capitalization of $78.04 million, a price-to-earnings ratio of -0.44 and a beta of 1.38. Pliant Therapeutics has a 1 year low of $1.09 and a 1 year high of $3.25. The business has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $1.44. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.94 and a quick ratio of 13.93.

About Pliant Therapeutics

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).